G
Gini F. Fleming
Researcher at University of Chicago
Publications - 361
Citations - 23484
Gini F. Fleming is an academic researcher from University of Chicago. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 66, co-authored 323 publications receiving 19686 citations. Previous affiliations of Gini F. Fleming include Gynecologic Oncology Group & Georgetown University.
Papers
More filters
Journal ArticleDOI
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: In this article, a double-blind, placebo-controlled, phase 3 trial was conducted to evaluate the effect of bevacizumab and paclitaxel on progression-free survival in patients with stage III or stage IV epithelial ovarian cancer.
Journal ArticleDOI
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson,Donald A. Berry,George D. Demetri,Constance Cirrincione,Lori J. Goldstein,Silvana Martino,James N. Ingle,M. Robert Cooper,Daniel F. Hayes,Katherine Tkaczuk,Gini F. Fleming,James F. Holland,David B. Duggan,John T. Carpenter,Emil Frei,Richard L. Schilsky,William C. Wood,Hyman B. Muss,Larry Norton +18 more
TL;DR: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
Journal ArticleDOI
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: This multinational double-blind placebo-controlled trial was designed to evaluate the addition of bevacizumab to standard front-line ovarian cancer therapy in patients with stage III or IV epithelial ovarian cancer.
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer EDITORIAL COMMENT
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: The use of bevacizumab during and up to 10 months after carboplatin and paclitaxel chemotherapy prolongs the median progression-free survival by about 4 months in patients with advanced epithelial ovarian cancer.
Journal ArticleDOI
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
Abram Recht,Stephen B. Edge,Lawrence J. Solin,David S. Robinson,Alison Estabrook,Richard E. Fine,Gini F. Fleming,Silvia C. Formenti,Clifford A. Hudis,Jeffrey J. Kirshner,David A. Krause,Robert R. Kuske,Amy S. Langer,George W. Sledge,Timothy J. Whelan,David G. Pfister +15 more
TL;DR: To determine indications for the use of postmastectomy radiotherapy (PMRT) for patients with invasive breast cancer with involved axillary lymph nodes or locally advanced disease who receive systemic therapy, an expert multidisciplinary panel reviewed pertinent information from the published literature.